Gliomas are the most common intracranial primary malignant tumors in adults. Among these， glioblastoma（ GBM） is highly malignant and carries an extremely poor prognosis. The current standard treatment for GBM involves maximal safe resection followed by adjuvant temozolomide chemotherapy and synchronous radiotherapy， but long-term outcomes remain poor. In recent years， immunotherapy has demonstrated significant potential in treating various non-glioblastoma tumors， with adoptive cellar immunotherapy achieving particularly promising clinical efficacy. In the field of adoptive cellar immunotherapy for gliomas， significant progress has been achieved in numerous preclinical studies and clinical trials. However， compared to other tumors， gliomas present a series of technical bottlenecks and efficacy limitations for the clinical application of adoptive cellar immunotherapy due to their unique biological characteristics. Nevertheless， adoptive cellar immunotherapy has opened new directions for research into treatment strategies for gliomas and offers potential hope for improving patient prognosis.